https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1467774/full
Frontiers | Eed-dependent histone modification orchestrates the iNKT cell developmental program...
Polycomb repressive complex 2 (PRC2) is an evolutionarily conserved epigenetic modifier responsible for tri-methylation of lysine 27 on histone H3 (H3K27me3)...
histone modificationinkt cellfrontierseeddependent
https://www.prnewswire.com/news-releases/fda-clears-agentus-ind-for-allogeneic-inkt-cell-therapy-301058578.html
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
/PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers...
inkt cellfdaclearsindallogeneic
https://www.southampton.ac.uk/research/projects/enhancing-neuroblastoma-immunogenicity-investigating-epigenetic-modulators-in
Enhancing Neuroblastoma Immunogenicity: Investigating Epigenetic Modulators in iNKT Cell Therapy |...
Enhancing Neuroblastoma Immunogenicity: Investigating Epigenetic Modulators in iNKT Cell Therapy.
inkt cellenhancingneuroblastomaimmunogenicityinvestigating
https://www.imperial.ac.uk/for-business/commercialisation/imperial-tech/technology-search/invariant-natural-killer-t-cell-inkt-cell-engagers/
Invariant Natural Killer T cell (iNKT cell) engagers | Imperial for business | Imperial College...
Invariant Natural Killer T cell (iNKT cell) engagers
natural killer t cellimperial for businessinvariant
https://www.marketscreener.com/quote/stock/ALPHA-COMPUTE-CORP-17185177/news/Portage-Biotech-Acquires-Outstanding-Minority-Interest-of-Invariant-Natural-Killer-T-cell-iNKT-A-41022434/
Portage Biotech : Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT)...
Jul 19, 2022 - Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell Agonist Platform Portage now holds 100% ownership of iOx Therapeutics...
natural killer t cell